Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oculis Holding AGOCS -0.47%26 EV-to-OCF is -5.25 as of Aug. 13, 2026. GuruFocus rates OCS with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,408 Biotechnology companies, Oculis Holding AG ranks better than 57.67% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Oculis Holding AG's Enterprise Value is $433.51 Mil.
Oculis Holding AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-82.58 Mil. Therefore, Oculis Holding AG's EV-to-OCF for today is -5.25.
The historical rank and industry rank for Oculis Holding AG's EV-to-OCF or its related term are showing as below:
OCS'
s EV-to-OCF Range Over the Past 10 Years
Min: -5.49 Med: 0 Max: -5.14
Current: -5.25
During the past 6 years, the highest EV-to-OCF of Oculis Holding AG was -5.14. The lowest was -5.49. And the median was .
OCS's EV-to-OCF is ranked better than 57.67% of 1408
companies
in the Biotechnology industry
Industry Median: -3.53
vs OCS: -5.25
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oculis Holding AG's PE Ratio (TTM) for today is calculated as:
Oculis Holding AG's share price for today is $12.82.
Oculis Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.751.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Oculis Holding AG EV-to-OCF Related Terms
Oculis Holding AG EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Oculis Holding AG's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oculis Holding AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oculis Holding AG EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oculis Holding AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Oculis Holding AG's EV-to-OCF falls into.
Oculis Holding AG's current Enterprise Value is $433.51 Mil.
Oculis Holding AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oculis Holding AG (OCS) has a EV-to-OCF of -5.25 as of Aug. 13, 2026. According to the industry distribution chart, Oculis Holding AG ranks #596 out of 1408 companies in the Biotechnology industry, placing it in the top 42.3%.
Is Oculis Holding AG's EV-to-OCF too high?
Oculis Holding AG's current EV-to-OCF is -5.25. Based on the distribution chart, Oculis Holding AG ranks #596 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oculis Holding AG has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's EV-to-OCF compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Oculis Holding AG ranks #596 out of 1408 companies for EV-to-OCF. This puts Oculis Holding AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Oculis Holding AG's current EV-to-OCF is -5.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (OCS) has a current EV-to-OCF of -5.25. The current EV-to-OCF is -5.25. Oculis Holding AG's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Oculis Holding AG (OCS), the current EV-to-OCF is -5.25 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
26GF Score
Get the complete analysis for OCS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCS has been successfully added to your 
